fda compounding semaglutide enforcement 2025 news issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Out of Shortage, Into Controversy:
Description
Common Side Effects Research on semaglutide indicates that gastrointestinal symptoms are most common
McEwen et al., 2012)
Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy
For clinicians and patients, the key point is that heart rate increases were observed, but they were generally modest, dose-related, and appeared to lessen over time
In addition, incretin enthusiasts had suffered a serious disappointment, when it was observed, at about the same time, that GIP although being potently insulinotropic in healthy individuals was ineffective in patients with type 2 diabetes (58)
